Tyvaso IPF Data In NEJM Reframes United Therapeutics Growth Potential [Yahoo! Finance]
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: Yahoo! Finance
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. United Therapeutics (NasdaqGS:UTHR) reported full Phase 3 TETON-2 trial data for nebulized Tyvaso in idiopathic pulmonary fibrosis, published in the New England Journal of Medicine. The study showed meaningful preservation of lung function and a reduction in clinical worsening for IPF patients treated with Tyvaso. If approved by the FDA, Tyvaso could become the first and only inhaled anti fibrotic treatment for IPF, expanding United Therapeutics' potential addressable market. United Therapeutics now has fresh late stage data on Tyvaso sitting in a top tier journal, which represents a clear milestone for any drug developer. With the shares at $536.12 and a 1 year return of 74.5%, the stock has already delivered strong gains for investors who have stayed the course. The 3 year and 5 year returns, at 144.0% and 215.2% respectively, show ho
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- What Moved Markets This Week [Seeking Alpha]Seeking Alpha
- United Therapeutics (UTHR) had its price target raised by Cantor Fitzgerald from $525.00 to $625.00. They now have an "overweight" rating on the stock.MarketBeat
- Asylon Robotics Announces New Advisors, Additions to Leadership Team [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of MedicineBusiness Wire
UTHR
Earnings
- 10/29/25 - Beat
UTHR
Sec Filings
- 3/16/26 - Form 144
- 3/16/26 - Form 4
- 3/16/26 - Form 4
- UTHR's page on the SEC website